|Bid||5.15 x 39400|
|Ask||5.17 x 1800|
|Day's Range||5.15 - 5.24|
|52 Week Range||5.15 - 7.45|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PLEASANTON, CA / ACCESSWIRE / April 21, 2021 /Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health to help prevent and better manage chronic diseases, today announced that it will report first quarter 2021 financial and operating results on Thursday, May 13, 2021.
As the pioneer of the first FDA-approved continuous glucose monitor, Dr. Mastrototaro will be integral in advancing the development and regulatory process of the Company's glucose and blood pressure monitoring technologyPLEASANTON, CA / ACCESSWIRE / March 25, 2021 / Today, Movano Inc.
PLEASANTON, CA / ACCESSWIRE / March 25, 2021 /Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, has closed its previously announced initial public offering of 8,500,000 shares of its common stock at a public offering price of $5.